What happens when patients require intensification from basal insulin? A retrospective audit of clinical practice for the treatment of type 2 diabetes from four Australian centres
Gregory Fulcher, Anthony Roberts, Ashim Sinha, Joseph Proietto
Diabetes Research and Clinical Practice | ELSEVIER IRELAND LTD | Published : 2015
AIMS: Little is known about clinical practices beyond the initiation of basal insulin in patients with type 2 diabetes mellitus (T2DM) in Australia. To determine the proportion of patients who progressed from basal insulin to each of three possible therapy groups: Group 1 addition of rapid-acting insulin, Group 2 switch to pre-mixed insulin, Group 3 addition of another therapy (incretin, glitazone, sulphonylurea, metformin, acarbose). METHODS: Retrospective audit across four Australian hospital clinics. Patients had a diagnosis of T2DM, basal insulin had been initiated and a subsequent treatment intensification/change had occurred during the analysis period (September 2007-March 2012). RESUL..View full abstract
This study was funded by Sanofi Australia Pty Ltd., the manufacturer of insulin glargine (Lantus (R)) and lixisenatide (Lyxumia (R)). The authors were responsible for the study design and protocol, representatives from Sanofi and Statistical Revelations Pty Ltd. (Annie Solterbeck and Robert Traficante) were responsible for the statistical analysis plan and analysis of the results. The sponsor reviewed the final manuscript before submission. The authors acknowledge editorial assistance in preparing the manuscript provided by Hazel Palmer CMPP (TM) formerly of Scius Solutions Pty Ltd. The contributions of Statistical Revelations Pty Ltd. and Scius Solutions Pty Ltd. were funded by Sanofi Australia Pty Ltd.